Work

A First-In-Human Study Evaluating the Safety and Pharmacology of Mm-151, a Novel Oligoclonal Anti-Egfr Antibody Combination in Patients with Refractory Solid Tumors

Year: 2014

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu331.17

Authors: W. Harb, C. Lieu, M. Beeram, L. Power, C. Sloss, J. Kearns, R. Nering, V. Moyo, B. Wolf, A.A. Adjei

Institutions: Horizon Oncology Center, University of Colorado Denver, South Texas Accelerated Research Therapeutics, Merrimack Pharmaceuticals (United States), Roswell Park Comprehensive Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2301071663

FWCI: 0.161

Cites:

Cited by: 2

Related to: 10